Santiago Haase

TL;DR: It is discovered that IDH1R132H expression in the genetic context of ATRX and TP53 gene inactivation increases median survival in the absence of treatment, enhances DNA damage response (DDR) via epigenetic up-regulation of the ataxia-telangiectasia–mutated (ATM) signaling pathway, and elicits tumor radioresistance.

TL;DR: New treatments and clinical approaches will emerge for glioma and other cancer types as mechanistic and molecular studies on ATRX are only just beginning to reveal the many critical functions of this protein in cancer.

TL;DR: It is demonstrated that metabolic reprogramming elicits anti-mIDH1 glioma immunity, leading to increased MS and immunological memory and the testing of IDH-R132H inhibitors in combination with IR/TMZ and anti-PDL1 as targeted therapy for mIDH 1/mATRX/mTP53 gliomas patients is supported.

TL;DR: A review of gene therapy-based anti-glioblastoma treatment can be found in this paper, where the authors highlight the progress, prospects and remaining challenges of gene therapies aiming at broadening our understanding and highlighting the therapeutic arsenal for GBM.

TL;DR: In this paper, the authors show that the efficacy of immune-stimulatory gene therapy (TK/Flt3L) is enhanced in mIDH1 gliomas, due to the reprogramming of the myeloid cells' compartment infiltrating the tumor microenvironment (TME).